About: Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 24 March 2014

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2014 (ast) наукова стаття, опублікована в березні 2014 (uk) scientific article published on 24 March 2014 (en) مقالة علمية نشرت في 24 مارس 2014 (ar)
publication date	wds:Q37702336-C31A3DAD-E1DD-44C2-B01E-108F7888965E
publication date	2014-03-24 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37702336-05B667A5-F75E-4EA7-ADC3-5D4C5944B0AD
language of work or name	English
cites work	wds:Q37702336-020FF01F-7BDE-4FCD-BE9C-E18C7322503E wds:Q37702336-0FAA272E-5DE5-4B2A-A990-74609729ED0D wds:Q37702336-18BEE5B0-226F-4AB1-BC8F-1FEB71B0F316 wds:Q37702336-1EBE127A-EE2A-44D0-A1BE-687F9C000B66 wds:Q37702336-202E41CE-02F5-414A-9799-60E331E94EED wds:Q37702336-2138684D-6DBF-4BA9-84E7-99C5226EFEC0 wds:Q37702336-2BDE84C5-8E76-42B0-98B4-12AE86B7E154 wds:Q37702336-334BA0FD-2E8F-4210-AE2D-D78D044CA67E wds:Q37702336-3CF21D2E-AC1C-45CE-B6B4-030418D10B79 wds:Q37702336-3D37CF49-A5D6-4CB9-942A-43CF240655D9 wds:Q37702336-43BAB794-0A20-4C35-95D3-051FEC2D1E01 wds:Q37702336-490D0226-DA01-407C-9501-C95B3BFEB4EC wds:Q37702336-4DDE08A8-C668-4544-B060-8EE78E198872 wds:Q37702336-635246A4-0BE0-441D-B0E0-FD05ED811976 wds:Q37702336-6F018083-9C8D-483B-A77E-2F231D84EC17 wds:Q37702336-79E0B0A9-4FED-48E6-9A87-DF65446B08A2 wds:Q37702336-9006E50A-07B7-47F9-A165-385FDC8B3684 wds:Q37702336-9B661FA9-AAEE-467A-9435-96D12178722E wds:Q37702336-9BD30255-7811-4F49-8D2A-C13A6D9189F3 wds:Q37702336-9C7985DF-A763-4B85-B4B9-73036697328D wds:Q37702336-9F335D96-540A-472D-AF33-F52B1B823CB6 wds:Q37702336-C2E2C367-57FB-43DB-A946-B9BF8D03D91F wds:Q37702336-DABB46F5-CAD6-4F31-BCC7-EF43321315E0 wds:Q37702336-E9FDC9B1-0186-4D00-A66C-5F934B8226D7 wds:Q37702336-EFA4E22E-76AE-49B4-81B0-346E23E09BC4 wds:Q37702336-F11E9D37-8260-41D4-881B-A8BE1A313F4E wds:Q37702336-FD34D9E5-310B-46E0-BCD7-DDD0A1D407B4
cites work	International scoring system for evaluating prognosis in myelodysplastic syndromes Report of an international working group to standardize response criteria for myelodysplastic syndromes. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Epigenetics in cancer Gene silencing in cancer in association with promoter hypermethylation Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation How I treat patients with myelodysplastic syndromes DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia Translating the histone code into leukemia Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches
author name string	wds:Q37702336-21038D79-7644-4B40-959B-D3081279D560 wds:Q37702336-35DFF729-342C-4245-B88F-35DB8C4FC6AB wds:Q37702336-54D3C020-C905-4A27-85E2-870BE7C68B7E wds:Q37702336-5869961D-E890-40BD-A29B-BD93E44A920A wds:Q37702336-84E17A3B-2793-4B1C-BA10-A0F1A9A66A91 wds:Q37702336-867E20C9-CD2E-46B0-B3E2-585D3941BE9A wds:Q37702336-BD67427F-AE6A-40DD-ABFC-E53BC12C2944 wds:Q37702336-C965E5C4-1D1C-4A67-A728-6B4A72FED76B wds:Q37702336-E827E651-B37F-44B2-9086-803B7523DA56 wds:Q37702336-EE55084F-9F8B-4117-B848-36C4D0674636
author name string	Janice Gabrilove Steven D Gore Martin S Tallman Ari Melnick Harry P Erba Zhuoxin Sun Peter L Greenberg James Herman Lisa Malick Mark Juckett
rdfs:label	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (en) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (nl) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (ast)
skos:prefLabel	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (en) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software